These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 32476509)

  • 61. Analysis of N6-Methyladenosine Methylation Modification in Fructose-Induced Non-Alcoholic Fatty Liver Disease.
    Luo Y; Zhang Z; Xiang L; Zhou B; Wang X; Lin Y; Ding X; Liu F; Lu Y; Peng Y
    Front Endocrinol (Lausanne); 2021; 12():780617. PubMed ID: 34950107
    [TBL] [Abstract][Full Text] [Related]  

  • 62. FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases.
    Tillman EJ; Rolph T
    Front Endocrinol (Lausanne); 2020; 11():601290. PubMed ID: 33381084
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Metabolic aspects of adult patients with nonalcoholic fatty liver disease.
    Abenavoli L; Milic N; Di Renzo L; Preveden T; Medić-Stojanoska M; De Lorenzo A
    World J Gastroenterol; 2016 Aug; 22(31):7006-16. PubMed ID: 27610012
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Gene-Environmental Interactions as Metabolic Drivers of Nonalcoholic Steatohepatitis.
    Albhaisi S; Sanyal AJ
    Front Endocrinol (Lausanne); 2021; 12():665987. PubMed ID: 34040583
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation.
    Younossi ZM; Marchesini G; Pinto-Cortez H; Petta S
    Transplantation; 2019 Jan; 103(1):22-27. PubMed ID: 30335697
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Discovering a critical transition state from nonalcoholic hepatosteatosis to nonalcoholic steatohepatitis by lipidomics and dynamical network biomarkers.
    Sa R; Zhang W; Ge J; Wei X; Zhou Y; Landzberg DR; Wang Z; Han X; Chen L; Yin H
    J Mol Cell Biol; 2016 Jun; 8(3):195-206. PubMed ID: 26993042
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Nonalcoholic Steatohepatitis: A Review.
    Sheka AC; Adeyi O; Thompson J; Hameed B; Crawford PA; Ikramuddin S
    JAMA; 2020 Mar; 323(12):1175-1183. PubMed ID: 32207804
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children.
    Kleiner DE; Makhlouf HR
    Clin Liver Dis; 2016 May; 20(2):293-312. PubMed ID: 27063270
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Clinical approaches to non-alcoholic fatty liver disease.
    Schwenger KJ; Allard JP
    World J Gastroenterol; 2014 Feb; 20(7):1712-23. PubMed ID: 24587650
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Non-alcoholic fatty liver disease: molecular and cellular interplays of the lipid metabolism in a steatotic liver.
    Ramos LF; Silva CM; Pansa CC; Moraes KCM
    Expert Rev Gastroenterol Hepatol; 2021 Jan; 15(1):25-40. PubMed ID: 32892668
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease.
    Negi CK; Babica P; Bajard L; Bienertova-Vasku J; Tarantino G
    Metabolism; 2022 Jan; 126():154925. PubMed ID: 34740573
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study.
    Wu YL; Lin ZJ; Li CC; Lin X; Shan SK; Guo B; Zheng MH; Li F; Yuan LQ; Li ZH
    Signal Transduct Target Ther; 2023 Mar; 8(1):98. PubMed ID: 36864020
    [TBL] [Abstract][Full Text] [Related]  

  • 74. From sugar to liver fat and public health: systems biology driven studies in understanding non-alcoholic fatty liver disease pathogenesis.
    Moore JB
    Proc Nutr Soc; 2019 Aug; 78(3):290-304. PubMed ID: 30924429
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Association between metabolic syndrome and liver histology among children with nonalcoholic Fatty liver disease.
    Patton HM; Yates K; Unalp-Arida A; Behling CA; Huang TT; Rosenthal P; Sanyal AJ; Schwimmer JB; Lavine JE
    Am J Gastroenterol; 2010 Sep; 105(9):2093-102. PubMed ID: 20372110
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
    Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
    World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Fructose as a key player in the development of fatty liver disease.
    Basaranoglu M; Basaranoglu G; Sabuncu T; Sentürk H
    World J Gastroenterol; 2013 Feb; 19(8):1166-72. PubMed ID: 23482247
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Genetic and Epigenetic Regulation in Nonalcoholic Fatty Liver Disease (NAFLD).
    Del Campo JA; Gallego-Durán R; Gallego P; Grande L
    Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562725
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The common marmoset as a model for the study of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Kramer JA; Grindley J; Crowell AM; Makaron L; Kohli R; Kirby M; Mansfield KG; Wachtman LM
    Vet Pathol; 2015 Mar; 52(2):404-13. PubMed ID: 24913270
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC.
    Kim H; Lee DS; An TH; Park HJ; Kim WK; Bae KH; Oh KJ
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.